Phase I study of liposomal annamycin in children and young adults with refractory or relapsed acute lymphocytic leukemia and acute myelogeneous leukemia.

Trial Profile

Phase I study of liposomal annamycin in children and young adults with refractory or relapsed acute lymphocytic leukemia and acute myelogeneous leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2011

At a glance

  • Drugs Annamycin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Jan 2009 Planned end date changed from 1 Aug 2008 to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 21 Feb 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top